Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.44 |
| ▸ | GUSB | P08236 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397507 | 0.90 | KDM4E (0.51) | HPGDLMNASMN1; SMN2PARP1GUSB | |
| SCHEMBL5063415 | 0.84 | HPGD (0.44) | HPGDNCOA1NCOA3LMNASMN1; SMN2 | |
| SCHEMBL15101407 | 0.72 | GRM2 (0.50) | NCOA1NCOA3IKBKBPARP1GRM2 | |
| Hydrochloric Acid SCHEMBL4972256 | 0.71 | GRM2 (0.44) | NCOA1NCOA3GRM2CHEK2 | |
| SCHEMBL28691005 | 0.70 | NCOA1 (0.60) | NCOA1NCOA3LMNASMN1; SMN2IKBKB | |
| SCHEMBL30412663 | 0.69 | RAB9A (0.75) | HPGDSMN1; SMN2PARP1KDM4ERAB9A | |
| SCHEMBL3698974 | 0.69 | RAB9A (0.75) | HPGDSMN1; SMN2PARP1KDM4ERAB9A | |
| SCHEMBL1336333 | 0.68 | HPGD (0.50) | HPGDLMNASMN1; SMN2PARP1GUSB | |
| SCHEMBL27461815 | 0.68 | KDM4E (0.54) | HPGDSMN1; SMN2IKBKBPARP1KDM4E | |
| SCHEMBL2422474 | 0.67 | HPGD (0.65) | HPGDLMNASMN1; SMN2KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101604-B2 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | claimed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | claimed |
| EP-1989203-A2 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-11-12 | — | — | EP | claimed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| WO-2007097981-A2 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-8101604-B2 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1989203-A2 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007097981-A2 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207997-A1 | Alpha carbolines and uses thereof | CHRM1, CNR1, CXCR1 | HPGD 1661/4885NCOA1 367/4885NCOA3 681/4885 |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | CHRM1, CNR1, CXCR1 | HPGD 1661/4885NCOA1 367/4885NCOA3 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.